External limiting membrane disruption predicts long-term outcome in strict Treat-and-Extend regimen in neovascular age-related macular degeneration
Author: Katja Hatz (Switzerland)
Co-authors: Laura Hoffmann
To determine long-term outcomes in visual acuity and outcome predicting factors in patients with neovascular age-related macular degeneration (nAMD) applying a strict treat-and-extend regimen (TER).
Retrospective study at Vista Eye Clinic Binningen, Switzerland.
Up to eight-year retrospective follow-up of treatment-naïve subjects with nAMD starting treatment with either ranibizumab or aflibercept in a strict TER without loading dose but with predefined exit criteria.
Two hundred-eleven (211) eyes of 187 patients with a mean follow-up of 60.3±20.9 months were included. Mean BCVA increased from initially 63.9±15.5 ETDRS letters (20/55) to 70.0±14.7 (20/40) after one year (+6.1 letters, p<0.001) and to 68.5±18.1 (20/43) (+4.6 letters, p=0.028) at 5 years. During follow-up 30.3% of eyes reached exit criteria. A worse BCVA (p=0.001) and a better external limiting membrane (ELM) disruption score at baseline predicted (p=0.019) BCVA gain at 5 years. The probability of reaching the exit criteria was significantly associated with a low central retinal thickness (CRT) (p=0.025), a better ELM disruption score (p=0.044) and the absence of a central pigment epithelial detachment (PED) (p=0.05) at baseline.
Significant visual gains were sustained after 5 years of follow-up in a TER in a real-world setting. Integrity of ELM at baseline predicted BCVA gain and anatomic disease stability at 5 years of treatment.
Dr Hoffmann has no conflicts of interests to disclose; PD Dr Hatz has received financial compensation from Novartis Switzerland, Bayer Switzerland, Alcon, Allergan and Roche for consultancies and contract research.
Secretariat Address European Society of Retina Specialists Ground Floor, The Apex Building Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2